Ginkgo Bioworks Holdings Inc. (Class A) (DNA) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Ginkgo Bioworks Holdings Inc. (Class A) (NYSE: DNA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $9.85 (-12.13% 1D, market cap $721.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DNA ranks #591 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DNA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ATTO (Attovia Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $693.4M) and SANA (Sana Biotechnology Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $769.4M). Among the 5-stock peer group, DNA leads on earnings multiple (N/A) while DNA leads on capital efficiency (-35.0% ROIC).
Per DNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001830214), Ginkgo Bioworks Holdings Inc. (Class A) generated $170.2M in revenue (-25.1% YoY), -$313.0K in net income, and -$178.7M in free cash flow against $1.12B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While DNA currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.74) and Max Pain ($10.34) forces dealer call-delta covering toward $19.13.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Ginkgo Bioworks Holdings Inc. (Class A) (DNA) dropped -12.13% to $9.85, trading at 35% of its 52-week range ($5.37 – $18.22). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
The Motley Fool report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, marking a -4.35% move from the prior day.
Ginkgo Bioworks has just agreed to open its Boston autonomous lab to National Science Foundation X-Labs teams, while also wiring Araceli’s high-speed imaging gear into its Nebula setup. For Ginkgo Bioworks shareholders,
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -25.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DNA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DNA. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Ginkgo Bioworks Holdings Inc. (Class A) (DNA) ranks #591 by composite RQD confidence (35/100, grade D-) and #392 by equity capitalization ($721.3M). Within this direct 5-issuer industry benchmark cohort, DNA leads on earnings valuation at N/A trailing P/E, while DNA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SLBT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with DNA at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DNA
ACTIVE
Ginkgo Bioworks Holdings Inc. (Class A) | D- | 35/100 | — | — | -35.0% | -12.13% | $721.3M | Benchmark Subject |
| ATTO Attovia Therapeutics Inc. | D | 44/100 | — | — | — | -0.92% | $693.4M | /atto-vs-dna → |
| SANA Sana Biotechnology Inc. | E | 33/100 | — | — | -35.0% | -6.61% | $769.4M | /sana-vs-dna → |
| SLBT SL Science Holding Limited | D | 45/100 | — | — | — | +5.83% | $672.9M | /slbt-vs-dna → |
| SLDB Solid Biosciences Inc. | E | 26/100 | — | — | -35.0% | -3.23% | $664.8M | /sldb-vs-dna → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ginkgo Bioworks Holdings Inc. (Class A) (DNA) reported GAAP revenue of $170.2M (-25.1% vs. FY2024 revenue of $227.0M , and -32.3% cumulative change since FY2023) , GAAP net income of -$313.0K, operating cash flow of -$171.1M, and free cash flow of -$178.7M (+53.2% YoY). On the balance sheet, DNA closed FY2025 with $1.12B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $170.2M | -$313.0K | -$171.1M | -$178.7M | $1.12B | — |
| FY2024 (FY) | 2024-12-31 | $227.0M | -$547.0K | -$319.6M | -$382.1M | $1.38B | — |
| FY2023 (FY) | 2023-12-31 | $251.5M | -$893.0K | -$295.5M | -$295.5M | — | — |
As of 2026-11-03, Ginkgo Bioworks Holdings Inc. (Class A) (NYSE: DNA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $9.85 (-12.13% 1D, market cap $721.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DNA ranks #591 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DNA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ATTO (Attovia Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $693.4M) and SANA (Sana Biotechnology Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $769.4M). Among the 5-stock peer group, DNA leads on earnings multiple (N/A) while DNA leads on capital efficiency (-35.0% ROIC).
Per DNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001830214), Ginkgo Bioworks Holdings Inc. (Class A) generated $170.2M in revenue (-25.1% YoY), -$313.0K in net income, and -$178.7M in free cash flow against $1.12B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
DNA last traded at $9.85 (-12.13% on volume of 3,550,864 shares), positioning the stock +1.13% above its 50-day simple moving average ($9.74) and +14.40% above its 200-day simple moving average ($8.61). Across its 52-week range of $5.37 to $18.22, DNA sits at the 34.9% percentile with a 14-day RSI of 51.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.62 to $11.08).
Ginkgo Bioworks Holdings Inc. (Class A) (DNA) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $9.85 (-12.13% 1D, market capitalization $721.3M).
. (Class A) is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. FY 2025 revenue was $170.2M, down from $227.0M in FY 2024, indicating the company generates revenue but at a declining rate across the reported periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Ginkgo Bioworks Holdings Inc. (Class A) (DNA) reported $170.2M in annual revenue (up from $227.0M in FY2024, -25.1% YoY) and -$313.0K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($251.5M revenue, -$893.0K net income) through FY2025, DNA scaled operating cash flow to -$171.1M and free cash flow to -$178.7M, backed by $1.12B in total assets against $0 in total debt.
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), DNA carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Ginkgo Bioworks Holdings Inc. (Class A) (DNA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
The Motley Fool report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on DNA here at $11.21: Institutional whale 13F flow scores 15 / 20, the strongest pillar in the Roarable RQD rating.. Compare DNA's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $10.65 are getting bought.
@DeltaGamma_99 Agree on the RQD 35/100 quality, though with 1.0 beta I'm scaling in with half-size at $11.21 and keeping dry powder in case we test $10.43.
Sitting on the sidelines or leaning short DNA above $11.21. ROIC of -35% and FCF yield of -21.8% show the business is consuming cash, with a Piotroski F-Score of 2/9.. Until Fundamental Cash Engine (7/20) and FCF yield (-21.8%) inflect higher, upside is capped near $18.22.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).